Our most comprehensive assay panel, screening for 520 clinically relevant genes as determined and recommended by the National Comprehensive Cancer Network. This gene panel screens for the majority of all actionable genetic mutations of interest within the oncology therapeutic development space.
Compatible with both tissue (Oncoscreen IO) and blood-based (Oncocompass IO) samples, the breadth of this diagnostic test allows for evaluation of complex biomarkers such as Tumor Mutational Burden (TMB), Microsatellite Instability (MSI), and Homologous Recombination Deficiency (HRD) as well as detection of specific rare mutations such as NTRK1-3 rearrangements, ALK fusions, and KRAS point mutations for treatment guidance of both targeted therapies and immunotherapies.
TMB (FDA approved June 2020) as a biomarker measures the total number of mutations found in DNA in cancer cells, and thus, gives predictive and prognostic value for determining cancer therapy. As this is our most comprehensive panel, Oncoscreen IO has applications for almost all cancer types. It can provide accurate genomic profiling for both clinical trial patient selection as well as therapy response monitoring.